摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-isopropyl-aniline; hydrochloride | 102439-84-9

中文名称
——
中文别名
——
英文名称
2-isopropyl-aniline; hydrochloride
英文别名
2-Isopropyl-anilin; Hydrochlorid;isopropylaniline hydrochloride;2-Propan-2-ylaniline;hydrochloride
2-isopropyl-aniline; hydrochloride化学式
CAS
102439-84-9
化学式
C9H13N*ClH
mdl
——
分子量
171.67
InChiKey
RMBRZDLUJUOCGL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.81
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    26
  • 氢给体数:
    2
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    2-isopropyl-aniline; hydrochloride碳酸氢钠 作用下, 以 甲醇氯仿 为溶剂, 反应 12.5h, 生成 1-(2-异丙苯基)-2-硫脲
    参考文献:
    名称:
    Synthesis of thiophene-2-carboxamidines containing 2-amino-thiazoles and their biological evaluation as urokinase inhibitors
    摘要:
    The serine protease urokinase (uPa) has been implicated in the progression of both breast and prostate cancer. Utilizing structure based design, the synthesis of a series of substituted 4-[2-amino- 1,3-thiazolyl]-thiophene-2-carboxamidine is described. Further optimization of this series by substitution of the terminal amine yielded urokinase inhibitors with excellent activities. (C) 2001 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(01)00102-0
  • 作为产物:
    描述:
    2-异丙基苯胺盐酸 作用下, 以 乙醇异丙醚 为溶剂, 生成 2-isopropyl-aniline; hydrochloride
    参考文献:
    名称:
    邻位效应对取代甲虫胺的酸性和碱性水解
    摘要:
    在一级条件下,在盐酸(0.01–8 M,20–60°C)和氢氧化物溶液(0.01–3 M,25和40°C)中测定了甲虫胺水解的动力学。在酸性条件下,使用二阶特定酸催化常数构建哈米特图。的邻使用藤田-西冈方法进行分析的效果。在碱性溶液中,水解显示出氢氧化物浓度的一阶和二阶依赖性。特定的基本催化常数用于构建Hammett图。评估了邻位效应对氢氧化物浓度的一级依赖性。甲酰苯胺通过特定的酸催化在酸性溶液中水解,动力学研究结果与A AC一致2机制。邻位取代由于共振的空间抑制,由于空间体积的阻滞以及空间相互作用而导致反应速率降低。碱性溶液中的主要水解途径与修饰的B AC 2机理一致。在0.10 M氢氧化钠溶液中,间位和对位取代的甲虫胺水解的哈米特图没有显示出取代基效应。然而,邻位取代导致速率常数的降低与取代基的空间体积成正比。
    DOI:
    10.1002/kin.20925
点击查看最新优质反应信息

文献信息

  • Synthesis and structure-activity studies of N,N'-diarylguanidine derivatives. N-(1-naphthyl)-N'-(3-ethylphenyl)-N'-methylguanidine: a new, selective noncompetitive NMDA receptor antagonist
    作者:N. L. Reddy、Lain-Yen Hu、R. E. Cotter、J. B. Fischer、W. J. Wong、R. N. McBurney、E. Weber、D. L. Holmes、S. T. Wong
    DOI:10.1021/jm00028a009
    日期:1994.1
    hylguanidine (40) showed high affinity for the NMDA receptor ion channel site (IC50 = 36 nM vs [3H]-3) and low affinity for sigma receptors (IC50 = 2540 nM vs [3H]-5). Selectivity for the NMDA receptor ion channel sites over sigma receptors appears to be dependent upon the structure of the additional substituents on the guanidine nitrogen atoms bearing the aryl groups. Methyl and ethyl substituents
    作为NMDA受体离子通道位点配体的二芳基胍代表了一类潜在的神经保护药物。合成了与N,N'-二邻甲苯基胍(DTG)(一种已知的选择性sigma受体配体)结构相关的几种二芳基胍,并使用NMDA受体在大鼠或豚鼠脑膜匀浆中进行了体外放射性配体置换试验,并进行了评估。离子通道位点特异性放射性配体[3H]-(+)-5(S)-甲基-10(R),11-二氢-5H-二苯并[a,d]环庚烯-5,10-亚胺(MK-801,3 ),以及sigma受体特异性放射性配体[3H]-二邻甲苯基胍(DTG,5)。本文介绍了导致新的三和四取代的胍的结构-活性关系,其对NMDA受体离子通道位点具有高选择性,对sigma受体的亲和力弱或微不足道。对称取代的二苯基胍的体外结合结果表明,在苯环上具有邻或间取代基(相对于胍氮的位置)的化合物与对位取代的衍生物相比,对NMDA受体离子通道位点的亲和力更高。在针对对称二芳基胍研究的一组环取
  • Atomic Insights into Synergistic Nitroarene Hydrogenation over Nanodiamond‐Supported Pt<sub>1</sub>−Fe<sub>1</sub> Dual‐Single‐Atom Catalyst
    作者:Pengcheng Deng、Jianglin Duan、Fenli Liu、Na Yang、Huibin Ge、Jie Gao、Haifeng Qi、Dan Feng、Man Yang、Yong Qin、Yujing Ren
    DOI:10.1002/anie.202307853
    日期:2023.9.4
    Abstract

    Fundamental understanding of the synergistic effect of bimetallic catalysts is of extreme significance in heterogeneous catalysis, but a great challenge lies in the precise construction of uniform dual‐metal sites. Here, we develop a novel method for constructing Pt1−Fe1/ND dual‐single‐atom catalyst, by anchoring Pt single atoms on Fe1−N4 sites decorating a nanodiamond (ND) surface. Using this catalyst, the synergy of nitroarenes selective hydrogenation is revealed. In detail, hydrogen is activated on the Pt1−Fe1 dual site and the nitro group is strongly adsorbed on the Fe1 site via a vertical configuration for subsequent hydrogenation. Such synergistic effect decreases the activation energy and results in an unprecedented catalytic performance (3.1 s−1 turnover frequency, ca. 100 % selectivity, 24 types of substrates). Our findings advance the applications of dual‐single‐atom catalysts in selective hydrogenations and open up a new way to explore the nature of synergistic catalysis at the atomic level.

    摘要从根本上理解双金属催化剂的协同效应在异相催化中具有极其重要的意义,但如何精确构建均匀的双金属位点是一个巨大的挑战。在此,我们开发了一种构建 Pt1-Fe1/ND 双单原子催化剂的新方法,将铂单原子锚定在装饰纳米金刚石(ND)表面的 Fe1-N4 位点上。利用这种催化剂,硝基烯烃选择性氢化的协同作用得以显现。具体来说,氢在 Pt1-Fe1 双位点上被激活,而硝基则通过垂直构型被强烈吸附在 Fe1 位点上,以进行后续氢化。这种协同效应降低了活化能,并产生了前所未有的催化性能(3.1 s-1 的周转频率,约 100 % 的选择性,24 种基质)。我们的发现推动了双单原子催化剂在选择性氢化中的应用,并为探索原子级协同催化的本质开辟了一条新途径。
  • Olefin polymerisation catalysts and processes for producing olefin polymers
    申请人:TOSOH CORPORATION
    公开号:EP0849292A1
    公开(公告)日:1998-06-24
    Catalysts for olefin polymerization which consist essentially of a transition metal compound, a modified clay compound and an organic aluminum compound, wherein the modified clay compound comprises a reaction product of a clay mineral and a proton acid salt of a specific amine compound, as well as a method of polymerizing olefins using such catalysts. It is possible thereby to obtain olefin polymers with high productivity and low ash content.
    烯烃聚合催化剂,主要由过渡金属化合物、改性粘土化合物和有机铝化合物组成,其中改性粘土化合物包括粘土矿物和特定胺化合物的质子酸盐的反应产物,以及使用这种催化剂聚合烯烃的方法。由此可以获得生产率高、灰分含量低的烯烃聚合物。
  • Synthesis and Pharmacological Evaluation of <i>N</i>-(2,5-Disubstituted phenyl)-<i>N</i>‘-(3-substituted phenyl)-<i>N</i>‘-methylguanidines As <i>N</i>-Methyl-<scp>d</scp>-aspartate Receptor Ion-Channel Blockers
    作者:Lain-Yen Hu、Junqing Guo、Sharad S. Magar、James B. Fischer、Kathleen J. Burke-Howie、Graham J. Durant
    DOI:10.1021/jm970459c
    日期:1997.12.1
    In the mammalian central nervous system, the N-methyl-D-aspartate (NMDA) subclass of glutamate receptors may play an important role in brain diseases such as stroke, brain or spinal cord trauma, epilepsy, and certain neurodegenerative diseases. Compounds which specifically antagonize the actions of the neurotransmitter glutamate at the NMDA receptor ion-channel site offer a novel approach to treating these disorders. CERESTAT (4, aptiganel CNS 1102) is currently undergoing clinical trial for the treatment of traumatic brain injury and stroke. Previously, we reported that analogues of N-1-naphthyl-N'-(3-ethylphenyl)-N'-methylguanidine (4) bound to the NMDA receptor ion-channel site with high potency and selectivity. Recently, molecules active at both a receptors and NMDA receptor sites were investigated. A series of substituted diphenylguanidines 6 which are structurally related to N-1-naphthyl-N'-(3-ethylphenyl)-N'-methylguanidine was prepared. Compounds containing appropriate substitution pattern in one of the phenyl rings of diphenylguanidines displayed high affinity. For example, N-(2,5-dibromophenyl)-N'-(3-ethylphenyl)-N'-methylguanidine (27b, R-2 = R-5 = Br, R-3 = C2H5) exhibited potency at both a receptors and NMDA receptor sites; 27b also showed high efficacy in vivo in a neonatal rat excitotoxicity model. Further studies indicated that substituent effects were important in this compound series, and 2,5-disubstituted phenyl was the preferred substitution pattern for high-affinity binding at NMDA receptor sites. Bromo and methylthio were the optimal substituents for the R-2 and R-5 positions of the 2,5-disubstituted phenyl group, respectively. N-(2-Bromo-5-(methylthio)phenyl)-N'-(3-ethylphenyl)- N'-methylguanidine (34b, R-2 = Br, R-5 = SMe, R-3 = C2H5) was highly active at NMDA receptor sites. We found that the binding affinity of guanidines of type 6 could be further enhanced with the appropriate substitution at R-3. Optimal activity in this series are afforded by 43b and 44b (R-2 = Cl or Br, R-5 = R-3 = SCH3). Both 43b and 44b bound to NMDA receptor sites with high potency and selectivity (K-i vs [H-3]MK-801: 1.87 and 1.65 nM, respectively); these compounds are active in vivo in various animal models of neuroprotection. The structure-activity relationships for-these compounds at the NMDA receptor ion-channel site are discussed.
  • Ligands with a 3,3-diphenylpentane skeleton for nuclear vitamin D and androgen receptors: Dual activities and metabolic activation
    作者:Shinnosuke Hosoda、Aya Tanatani、Ken-ichi Wakabayashi、Makoto Makishima、Keisuke Imai、Hiroyuki Miyachi、Kazuo Nagasawa、Yuichi Hashimoto
    DOI:10.1016/j.bmc.2006.04.039
    日期:2006.8
    Ligands possessing dual vitamin D-3 (VD3)-agonistic and androgen-antagonistic activities with various activity spectra were prepared based on a substituted 3,3-diphenylpentane (DPP) skeleton. Among the compounds, (R,S)-DPP-1023 [(R,S)-7b] and (S,S)-DPP-0123 [(S,S)-7c] showed the most potent vitamin D-3-agonistic activity [with potency comparable to that of 1 alpha,25-dihydroxyvitamin D-3 (1,25-VD3)] and nuclear androgen receptor (AR)-binding activity (with higher affinity than that of hydroxyflutamide), respectively. Metabolic activation (reduction of the carbonyl group) of pivaloyl analogs [DPP- 1113 (3a), DPP- 10 13 (3b), DPP-0113 (3c), and DPP-0013 (3d)] in HL-60 cells was found to be necessary for binding to nuclear vitamin D-3 receptor (VDR). (c) 2006 Elsevier Ltd. All rights reserved.
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐